MONTREAL, QUEBEC--(Marketwire - Aug. 10, 2007) - Ambrilia Biopharma Inc. (TSX:AMB), a biopharmaceutical company developing novel small molecules and peptides to treat infectious diseases and cancer, announced today the second quarter 2007 financial results and provided an update on its development program
HIV INTEGRASE INHIBITOR PROGRAM
The preclinical data presented recently at the XVI International HIV Drug Resistance Workshop showed that Ambrilia's new series of integrase inhibitors (pyrazolopyridine compounds) had a good activity against HIV-1 viruses, without significant cytotoxicity.
Furthermore, cross-competition kinetic studies with known competitive strand transfer inhibitors (such as diketo acid compounds) suggested a different mechanism of action, which may lead to a different resistance profile from known strand transfer inhibitors currently in clinical development by pharmaceutical companies. The Company has currently identified a number of lead compounds for optimization and aims to have a potential preclinical drug candidate within the next 12 months.
read more
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment